Similar articles

Abstract: Objective: To study the effects of the generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide (G4PAMAM/VEGFASODN) compound on the expressions of vascular endothelial growth factor (VEGF) and its mRNA of breast cancer cells and on the inhibition of vascular endothelial cells. Methods: We examined the morphology of G4PAMAM/VEGFASODN compound and its pH stability, in vitro transfection efficiency and toxicity, and the expressions of VEGF and its mRNA. Methyl thiazolyl tetrazolium assay was used to detect the inhibitory function of the compound on vascular endothelial cells. Results: The compound was about 10 nm in diameter and was homogeneously netlike. From pH 5 to 10, it showed quite a buffered ability. The 48-h transfection rate in the charge ratio of 1:40 was 98.76%, significantly higher than that of the liposome group (P<0.05). None of the transfection products showed obvious toxicity on the cells. The expressions of both VEGF protein and its mRNA after G4PAMAM/VEGFASODN transfection decreased markedly. Conclusion: With a low toxicity, high safety, and high transfection rate, G4PAMAM/VEGFASODN could be a promising gene vector. Specifically, it inhibits VEGF gene expression efficiently, laying a basis for further in vivo animal studies.

[1] Alton, E., 2007. Progress and prospects: gene therapy clinical trials (part 1). Gene Ther., 14(20):1439-1447.

[2] Bertolini, F., Mancuso, P., Shaked, Y., Kerbel, R.S., 2007. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov. Today, 12(19-20):806-812.

[3] Devarakonda, B., Otto, D.P., Judefeind, A., Hill, R.A., de Villiers, M.M., 2007. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int. J. Pharm., 345(1-2):142-153.

[4] Edelstein, M.L., Abedi, M.R., Wixon, J., 2007. Gene therapy clinical trials worldwide to 2007—an update. J. Gene Med., 9(10):833-842.

[5] Esfand, R., Tomalia, D.A., 2001. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today, 6(8): 427-436.

[6] Flotte, T.R., 2007. Gene therapy: the first two decades and the current state-of-the-art. J. Cell. Physiol., 213(2):301-305.

[7] Guo, C., Wang, H., Lin, Y., Cai, Q., 2004. Application of Starburst (TM) PAMAM dendrimers as DNA carriers in vitro. Prog. Biochem. Biophys., 31(9):804-811.

[8] Hattori, Y., Ding, W., Maitani, Y., 2007. Highly efficient cationic hydroxyethylated cholesterol-based nanoparticle-mediated gene transfer in vivo and in vitro in prostate carcinoma PC-3 cells. Journal of Controlled Release, 120(1-2):122-130.

[9] Hayes, D.F., Miller, K., Sledge, G., 2007. Angiogenesis as targeted breast cancer therapy. Breast, 16(2):17-19.

[10] Miller, A.D., 2003. The problem with cationic liposome/ micelle-based non-viral vector systems for gene therapy. Curr. Med. Chem., 10(14):1195-1211.

[11] Mo, Z., Liu, Y., Chen, H., Li, H., Sun, Y., 2007. Preparation and molecular dynamics simulation of Sm/PAMAM nano-composite. Rare Metal. Mat. Eng., 36(1):32-36 (in Chinese).

[12] Schiavone, N., Donnini, M., Nicolin, A., Capaccioli, S., 2004. Antisense oligonucleotide drug design. Curr. Pharm. Design, 10(7):769-784.

[13] Vattemi, E., Claudio, P.P., 2007. Advances and perspectives in gene-based therapy for breast cancer. Drug Future, 32(6):507-516.

[14] Wang, Y., Boros, P., Liu, J., Qin, L., Bai, Y., Bielinska, A.U., Kukowska-Latallo, J.F., Baker, J.R., Bromberg, J.S., 2000. DNA/dendrimer complexes mediate gene transfer into murine cardiac transplants ex vivo. Mol. Ther., 2(6): 602-608.

[15] Yoo, H., Juliano, R.L., 2000. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res., 28(21):4225-4231.

[16] Zelnak, A.B., O′Regan, R.M., 2007. Targeting angiogenesis in advanced breast cancer. BioDrugs, 21(4):209-214.